logo
South Korean officials, business leaders in Washington to push for U.S. trade deal

South Korean officials, business leaders in Washington to push for U.S. trade deal

Globe and Mail3 days ago
Three cabinet-level South Korean officials met U.S. Commerce Secretary Howard Lutnick in Washington for trade talks, Seoul said on Wednesday, as top business leaders were also reported to be flying in to help lobby for a deal on U.S. tariffs.
South Korean Finance Minister Koo Yun-cheol joined Industry Minister Kim Jung-kwan and Minister for Trade Yeo Han-koo, who have been in Washington since last week, for two hours of talks with Lutnick, a ministry spokesperson said in Seoul. The finance ministry spokesperson did not offer details of the discussions. U.S. President Donald Trump has set an August 1 deadline for 25% tariffs to kick in against South Korea, a major U.S. ally and powerhouse exporter of chips, cars and steel.
The South Korean government is negotiating with the U.S. by 'setting up a package that focuses on areas where South Korea and the U.S. can achieve mutually beneficial results to the extent that we can bear them,' the presidential office said in a statement.
South Korean President Lee Jae Myung told his ministers to 'engage in the difficult consultation with confidence' as he was briefed on the status of the talks on Wednesday, his office said.
The latest meeting came as the Wall Street Journal reported that Lutnick had urged the South Korean team to bring their best and final offer to the table during a meeting he had with Kim and Yeo in Scotland.
Lutnick told the South Korean officials they need to 'bring it all' when they make their final offer to Trump, the report said.
Trump says India deal not finalized, warns of higher tariffs before August deadline
Mexico grapples with Trump's unrelenting demands
South Korea's benchmark KOSPI stock index rose 0.7% on Wednesday to hit a near four-year high, as the flurry of U.S. visits by government and company officials raised optimism around the country's trade negotiations. Koo, who arrived in Washington on Tuesday, has said he hopes to convince the United States the package of trade and related offers of industrial co-operation, including in shipbuilding, is to the allies' mutual benefit.
Koo also plans to meet U.S. Treasury Secretary Scott Bessent during the visit.
The heads of some of South Korea's largest global companies were converging on Washington to lend support to government negotiators, media reports said. Hyundai Motor Group Chairman Euisun Chung was reported to be departing for Washington on Wednesday.
Samsung Electronics Chairman Jay Y. Lee and the vice chairman of the Hanwha Group, Kim Dong-kwan, whose affiliate Hanwha Ocean has unveiled a major investment plan in the United States, were also in Washington, D.C.
Hyundai Motor, which along with its affiliate Kia Corp is the world's third-largest auto maker, will face a significant impact in the absence of a waiver or reduction in a 25% import duty on cars given that the U.S. is a major export destination.
South Korean officials were also discussing potential co-operation in chips, batteries and biotechnology under a package proposal, South Korea's chief presidential policy secretary Kim Yong-beom said.
Kim Yong-beom said last week currency policy had not been part of trade negotiations with the U.S. beyond regular consultations, but a foreign exchange official travelled to Washington to be prepared if the U.S. raises the issue, according to the finance ministry.
In late April, South Korea agreed to consult on foreign exchange via a separate channel at the opening round of trade talks. Pressure has been mounting on South Korea since Japan clinched a deal to cut Trump's threatened tariffs to 15% last week.
This was followed by a U.S.-EU trade deal over the weekend, and Trump's top aides, including Bessent, are now working to close a deal with China. South Korean Foreign Minister Cho Hyun is also travelling to Washington this week to assist with the tariff negotiations.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

AstraZeneca's AZD3427 Study: A Potential Game-Changer for Heart Failure and Pulmonary Hypertension
AstraZeneca's AZD3427 Study: A Potential Game-Changer for Heart Failure and Pulmonary Hypertension

Globe and Mail

timean hour ago

  • Globe and Mail

AstraZeneca's AZD3427 Study: A Potential Game-Changer for Heart Failure and Pulmonary Hypertension

AstraZeneca ((AZN)), Parexel International ((PRXL)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. AstraZeneca, in collaboration with Parexel International, is conducting a Phase IIb study titled A Phase IIb Randomised, Double-blind, Placebo-controlled, Multi-centre, Dose-ranging Study of AZD3427 in Participants With Heart Failure and Pulmonary Hypertension Due to Left Heart Disease (WHO Group 2). The study aims to assess the efficacy of AZD3427 in reducing pulmonary vascular resistance in patients with heart failure and pulmonary hypertension over 24 weeks, highlighting its potential significance in treating these conditions. The intervention being tested is AZD3427, administered as a subcutaneous injection. It is designed to target pulmonary hypertension by reducing vascular resistance, with the study evaluating three different dose levels of the drug. The study follows a randomized, parallel assignment model with triple masking, involving participants, care providers, and investigators. Its primary purpose is treatment-focused, aiming to determine the optimal dosing strategy for AZD3427. The study began on April 24, 2023, with an estimated completion date in July 2025. These timelines are crucial for tracking the progress and potential market introduction of AZD3427. The outcome of this study could significantly impact AstraZeneca's market position, potentially boosting its stock performance if results are positive. Investors will be keenly watching for updates, especially in the context of competitive treatments for heart failure and pulmonary hypertension. The study is ongoing, with further details available on the ClinicalTrials portal.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store